Modakafusp alfa

DRUG4 trials

Sponsors

Teva Branded Pharmaceutical Products R&D LLC

Conditions

MelanomaMultiple MyelomaNeoplasms

Phase 1

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

TerminatedNCT03215030

Teva Branded Pharmaceutical Products R&D LLCMultiple Myeloma

Start: 2017-10-04End: 2024-11-07Updated: 2026-01-29

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

TerminatedNCT04157517

Teva Branded Pharmaceutical Products R&D LLCMelanoma, Neoplasms

Start: 2019-12-12End: 2023-12-20Updated: 2026-01-29

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

TerminatedNCT05556616

Teva Branded Pharmaceutical Products R&D LLCMultiple Myeloma

Start: 2023-01-12End: 2024-06-04Updated: 2026-01-29

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

TerminatedNCT05590377

Teva Branded Pharmaceutical Products R&D LLCMultiple Myeloma

Start: 2023-01-23End: 2024-05-22Updated: 2026-01-30

Related Papers

A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.

2025-12-08

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Blood2025-04-251 citations

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Blood2024-12-046 citations

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood2024-11-05

Abstract CT065: Modakafusp alfa shows intratumoral immune pharmacodynamics (PD) in a subset of patients (pts) in a phase 1b study in advanced/metastatic solid tumors

Cancer Research2024-04-05

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Blood2023-11-024 citations

PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)

HemaSphere2023-08-011 citations

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood2022-11-1511 citations

S181: MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere2022-06-014 citations

Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors.

Journal of Clinical Oncology2022-06-011 citations

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

Blood2021-11-0516 citations

TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

Blood2020-11-0519 citations

357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma

Regular and Young Investigator Award Abstracts2020-11-014 citations